Capecitabine antineoplastic

Drugs of the Future

Volumn 21, Issue 4, 1996, Pages 358-360

  Hoshi, Akio ^a   Castaner J ^a,b  

^a Prous Science Publishers ^*  (Japan)

^b PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOXIFLURIDINE; DRUG METABOLITE; FLUOROURACIL DERIVATIVE; GALOCITABINE; PRODRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ESOPHAGUS CANCER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

EID: 0030011380     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.04.353124     Document Type: Article

References (11)

1. Arasaki, M., Ishitsuka, H., Kurama, I., Miwa, M., Murasaki, C., Shimma, N., Umeda, I. (F. Hoffmann-La Roche AG). N-Oxycarbonyl substd. 5′-deoxy-5-fluorocytidines. EP 602454, JP 94211891, US 5472949.
2. 4-pentyloxycarbonyl-5′-DFCR. 53rd Annu Meet Jpn Cancer Assoc (Oct 19-21, Nagoya) 1994, Abst 2410.
3. Ishitsuka, H., Miwa, M., Ishikawa, T. et al. Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Proc Amer Assoc Cancer Res 1995, 36: Abst 2426.
4. Ura, M., Sawada, N., Nishida, M., Miwa, M., Arasaki, M., Murasaki, C., Umeda, I., Shimma, N., Ishitsuka, H. Novel 5′-deoxy-5-fluorocytidine (5′-DFCR) derivative Ro 09-1978. 53rd Annu Meet Jpn Cancer Assoc (Oct 19-21, Nagoya) 1994, Abst 2407.
5. Umeda, I., Arasaki, M., Murasaki, C., Masubuchi, K., Kohchi, Y., Kuruma, I., Miwa, M., Ura, M., Ishitsuka, H., Shimma, N. Synthesis and bioconversion efficiency of novel prodrug of furtulon. 53rd Annu Meet Jpn Cancer Assoc (Oct 19-21, Nagoya) 1994, Abst 2408.
6. Tahara, H., Odagiri, H., Ishikawa, T., Kuruma, I. Pharmacokinetics of novel fluoropyrimidine derivative (Ro 09-1978) in monkey. 53rd Annu Meet Jpn Cancer Assoc (Oct 19-21, Nagoya) 1994, Abst 2409.
7. Kawashima, A., Horii, I. Novel 5′-DFCR derivative Ro 09-1978: Improvement of intestinal toxicity. 53rd Annu Meet Jpn Cancer Assoc (Oct 19-21, Nagoya) 1994, Abst 2411.
8. Roche Annual Report 1994.
9. Meropal, N.G., Budman, D.R., Creaven, P.J., Lichtman, S., Berghom, E., Behr, J., Gordon, R.J., Osterwalder, B. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 298.
10. Hughes, M., Planting, A., Twelves, C., Schellens, J., Allman, D., Osterwalder, B., Kaye, S., Verweij, J. A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer. 9th NCI-EORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 297.
11. Taguchi, T., Ishitani, K., Saitoh, K. et al. A Japanese phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. 9th NCIEORTC Symp New Drugs Cancer Ther (March 12-15, Amsterdam) 1996, Abst 299.